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Abstract
Background: Nutrition therapy is the cornerstone of treating diabetes mellitus. The inclusion of fish (particularly oily
fish) at least two times per week is recommended by current international dietary guidelines for type 2 diabetes. In
contrast to a large number of human studies examining the effects of oily fish on different cardiovascular risk factors,
little research on this topic is available in patients with type 2 diabetes. The aims of this pilot study were to investigate
the effects of a sardine-enriched diet on metabolic control, adiponectin, inflammatory markers, erythrocyte membrane
fatty acid (EMFA) composition, and gut microbiota in drug-naïve patients with type 2 diabetes.
Methods: 35 drug-naïve patients with type 2 diabetes were randomized to follow either a type 2 diabetes standard
diet (control group: CG), or a standard diet enriched with 100 g of sardines 5 days a week (sardine group: SG) for
6 months. Anthropometric, dietary information, fasting glycated hemoglobin, glucose, insulin, adiponectin,
inflammatory markers, EMFA and specific bacterial strains were determined before and after intervention.
Results: There were no significant differences in glycemic control between groups at the end of the study. Both
groups decreased plasma insulin (SG: −35.3 %, P = 0.01, CG: −22.6 %, P = 0.02) and homeostasis model of
assessment - insulin resistance (HOMA-IR) (SG: −39.2 %, P = 0.007, CG: −21.8 %, P = 0.04) at 6-months from
baseline. However only SG increased adiponectin in plasma compared to baseline level (+40.7 %, P = 0.04). The
omega-3 index increased 2.6 % in the SG compared to 0.6 % in the CG (P = 0.001). Both dietary interventions
decreased phylum Firmicutes (SG and CG: P = 0.04) and increased E. coli concentrations (SG: P = 0.01, CG: P = 0.03)
at the end of the study from baseline, whereas SG decreased Firmicutes/Bacteroidetes ratio (P = 0.04) and
increased Bacteroides-Prevotella (P = 0.004) compared to baseline.
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Conclusions: Although enriching diet with 100 g of sardines 5 days a week during 6 months to a type 2
diabetes standard diet seems to have neutral effects on glycemic control in drug-naïve patients with type 2
diabetes, this nutritional intervention could have beneficial effects on cardiovascular risk. Furthermore, both
dietary interventions decreased HOMA-IR and altered gut microbiota composition of drug-naïve patients with
type 2 diabetes.
Trial registration: Trial number and name of the registry: NCT02294526, ClinicalTrials.gov
Keywords: Type 2 diabetes, Pilot trial, Nutrition therapy, Oily fish, Sardine
Background
Type 2 diabetes (T2D) is becoming a global epidemic
affecting more than 340 millions of people around the
world [1]. It is necessary to explore direct and effective
approaches in order to minimize and prevent macrovas-
cular and microvascular complications associated with
T2D. Nutrition therapy is the cornerstone of treating
diabetes mellitus [2], and current international dietary
guidelines recommend the inclusion of fish (particularly
oily fish) at least two times per week for subjects with
T2D [2, 3].
The omega-3 index (O3I) is the eicosapentanoic acid
(EPA) + docosahexanoic acid (DHA) content in erythro-
cytes expressed as a percentage of total identified fatty
acids. Besides to be the main determinant of long chain
n-3 polyunsaturated fatty acids (LCn-3PUFAs) intake,
the O3I is considered as a novel cardiovascular risk
factor [4]. The fact that supplements of seafood-derived
n-3 (omega 3) failed to improve insulin metabolism in
patients with T2D [5] prompted the hypothesis that
nutrients other than omega-3 fatty acids may contribute
to the beneficial effects of fish in T2D. These nutrients
include fish protein and specific amino acids, particularly
taurine, an essential amino acid which can be found
abundantly in sardines (Sardina pilchardus) [6]. In this
regard, rats with diabetes and metabolic syndrome
improved insulin resistance, inflammatory status and
hyperglycemia after a diet supplemented with proteins
obtained from sardines [6, 7]. This overall makes sar-
dine consumption an appealing strategy to limit the
complications of T2D.
However, the question of whether regular sardine intake
without use of oral hypoglycemic agents improves meta-
bolic control and insulin resistance in patients with T2D
remains to be explored. To address this issue, we studied
the effect of enriching the diet of drug-naïve T2D patients
with 100 g of sardines (the average daily consumption of
seafood in Spain [8] 5 days a week for 6 months, searching
for changes in metabolic control. As secondary endpoints,
we assessed changes in erythrocyte membrane fatty acid
(EMFA) profile, adiponectin, inflammatory markers and
gut microbiota (GM), whose composition is associated to
pathological conditions such as obesity and T2D [9].
Methods
Subjects
The Pilchardus Study was a multicenter randomized, nu-
tritional pilot trial conducted between October 2012 and
November 2013 in free-living men and women who were
overweight or obese [body mass index (BMI) between 26
and 35 kg/m2]. Candidate subjects were eligible if they
had been diagnosed with T2D according to the American
Diabetes Association (ADA) criteria [10] and if their gly-
cated haemoglobin (HbA1c) levels were between 6.0 and
8.0 % following standard diabetes dietary recommenda-
tions. In addition, to be included in the study, participants
could not be undergoing treatment with insulin and/or
oral antidiabetic drugs, were aged between 40 and 70 year
and consumed less than 3 servings of fish per week.
Exclusion criteria were either acute cardiovascular or
cerebrovascular events diagnosed during the 2 months
prior to randomization; changes in chronic medication
during the 3 months prior to randomization; treatment
with oral steroids or non steroidal anti-inflammatory
drugs for more than 5 days during the month prior to
randomization; intake of omega 3 supplements; and
allergy to fish or fish protein.
All procedures used in the study protocol were ap-
proved by the Clinical Research Ethics Committees of the
three study centers involved (Hospital Clínic of Barcelona,
Hospital Vall d’Hebron of Barcelona, and Hospital Carlos
Haya of Málaga). Written informed consent to participate
in the study and to publish individual data were obtained
from all subjects prior to the start of the study.
Study design
The Pilchardus Study consisted of a 2-week lead-in
period, followed by a 6-month dietary intervention
study. Sixty-two subjects were recruited and screened
from the Endocrinology and Nutrition outpatient depart-
ments of the three different hospitals (Hospital Clínic,
Hospital Vall d’Hebron, Hospital Carlos Haya) and from
the Primary Health Care Centres participating in the
study. Finally, sixteen men and nineteen women (60.6 ±
1.4 years) were enrolled. Participants were randomly allo-
cated either to sardine group (SG) or to control group
(CG). The method used to generate the random allocation
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sequence was an online randomization software. An exter-
nal person from the trial staff was in charge of allocating
subjects to CG or SG as appropiate.
Participants in the SG (n = 19) followed a standard diet
for T2D enriched with 100 g of sardines 5 days a week
during 6 months. Each subject in SG replaced 100 g of
their usual protein foods intake by 100 g of sardines.
Participants in the CG (n = 16) followed a standard diet for
T2D during 6 months without sardine’s supplementation.
The nutritional intervention aimed to control individ-
ual carbohydrate portions and modify the quality of diet-
ary protein and fat with no specific caloric restriction, in
order to avoid a possible interference of a high weight
loss in study results. The only difference between diets
in the two intervention groups was that subjects in the
SG replaced 100 g of their usual protein foods intake by
100 g of sardines, therefore both dietary interventions
had the same nutrient composition except for the type
of protein and fat coming from sardines.
Participants in the SG were provided with a free sup-
ply of sardines to cover the entire interventional period.
This included sardines canned in olive oil and sardine-
based products developed by Alícia [11], such as sardine
hamburgers, croquettes and paté, all of which contained
either 50 or 100 g of canned sardines in olive oil per
serving. Moreover, a variety of dishes featuring fresh and
canned sardines were developed by Alícia to increase the
variety of recipes used in the sardine diet. The canned
sardines were given to patients during the monthly visits
with the dietitian, and the sardine-based products were
sent home, frozen, at the intervention onset and at
3 months.
Dietary intake and dietary habits of all the participants
were assessed by a 3-day dietary record at baseline and
during the last week of the dietary interventional period.
Nutritional composition was analysed by Easy Diet® on-
line software, and total LCn-3PUFAs, EPA +DHA and
taurine intakes were analysed by DIAL 1.0 ® software.
Nutritional compliance to sardine diet was assessed at
the end of dietary intervention by O3I and monthly by
Food Frequency Questionnaire (FFQ). Incompliance was
defined as consumption of less than 300 g of sardines
per week during one month.
During the 2-week lead-in period prior to the start of
the nutritional intervention, patients attended two ses-
sions of dietary education. Expert dietitians from the
Endocrinology and Nutrition Departments implemented
a dietary education program focused on developing the
knowledge and skills needed to follow the nutritional
prescription used in the study. During the 6-month fol-
low-up period of the study, the same dietitians perfomed
monthly follow-up visits with each subject (Fig. 1).
Clinical measurements and biochemical analysis
At baseline and at the end of the intervention, we ob-
tained anthropometric data and overnight fasted blood
samples. Aliquots of blood and plasma were immediately
frozen and stored at −80 °C until analysis. All biochem-
ical measurements were analyzed at the Biomedical
Fig. 1 Design of Pilchardus study
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Diagnostic Center of Hospital Clinic of Barcelona and at
the IDIBAPS Diabetes and Obesity Research Laboratory.
For HbA1c determination, an aliquote of whole blood
was refrigerated and was analyzed within the first 48 h.
Glucose was determined by enzymatic method (ADVIA
2400 Chemistry Analyzer, Siemens Healthcare Diagnos-
tics, Tarrytown, NY), and insulin by chemiluminometric
immunoassay (ADVIA Centaur Immunochemistry analyzer,
Siemens Healthcare Diagnostics, Tarrytown, NY). Insulin
resistance was calculated according to homeostasis model
of assessment - insulin resistance (HOMA-IR); HOMA-IR
= insulin (mU/ml) × fasting plasma glucose (mmol/l)/22.5,
with units expressed as mmol/L. Plasma total adiponectin
was determined by commercial ELISA kits (Mercodia AB,
Uppsala, Sweden). Plasma interleukin 6 (IL-6) and IL-10
were determined by commercial Cytometric Bead Array
(BD™, New Jersey, USA). Plasma tumor necrosis factor
alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP)
and IL-8 were determined at the Biomedical Diagnostic
Center of Hospital Clinic of Barcelona. Whole blood cell
membrane fatty acids were determined by GC (Agilent
6890 Gas Chromatograph HP 6890 with capillary column,
autosampler and flame ionization detector) as described
[12]. Each fatty acid is expressed as a percentage of total
identified fatty acids in the whole blood sample. The O3I
was calculated by the sum of percentages of EPA+DHA.
Gut microbiota composition
Genomic DNA was extracted from fecal samples by
using the PSP® Spin Stool DNA Plus kit (Stratec, Berlin,
Germany). DNA quantity and purity was checked with
NanoDrop ND-100 spectrophotometer. Shifts in micro-
biota were determined by quantifying the abundance of
target bacterial indicators previously associated with
T2D by quantitative PCR (qPCR). In particular, we com-
pared the abundance of Faecalibacterium prausnitzii,
Escherichia coli (E. coli), Eubacterium rectale – Clostrid-
ium coccoides, Bacteroides – Prevotella, Firmicutes and
the Firmicutes/Bacteroidetes ratio. (Primers, probes,
standards for quantification, and PCR conditions are
detailed in Additional file 1).
Statistical analysis
Descriptive data are presented as the mean or median
and standard error (SE) for continuous outcomes, or the
number for categorical outcomes. The non-parametric
Wilcoxon test for paired data was performed for com-
parisons between final and baseline values, whereas the
U-Mann Withney test was used to compare non-paired
data at baseline. Primary and secondary outcomes at
6 months were tested using analysis of covariance
(ANCOVA). Statistical analyses were performed using
SPSS 18 for Windows (SPSS, Inc., Chicago, IL, USA). P
values less than 0.05 were considered statistically
significant.
Results
Baseline subjects characteristics and drop-outs
Baseline characteristics of the participants were not sig-
nificantly different between the two groups (Table 1,
Additional file 2). All of them were overweight or obese,
had HbA1c values over 6.5 % and had insulin levels be-
tween 14.6 and 17.1 mU/L (Table 1). Two subjects of SG
were discontinued from the study, both for incompliance
with the sardine diet. In the CG, one subject was unable to
complete the study due to cancer diagnosis. Of the thirty-
five randomized subjects selected to enter the study, a total
of thirty-two completed the six-month intervention. Six SG
subjects and two CG subjects had no final dietary data;
therefore, the changes in dietary intake for these subjects
were not included in the analyses performed (Fig. 2).
Body composition and dietary intake
There were no significant changes in body weight be-
tween SG and CG at the end of dietary interventions
(Table 1). The analyses of 3-day food records showed
that the greatest significant differences between groups
at 6 months were for nutrients derived from sardine
consumption. Total LCn-3PUFA, EPA+DHA and taurine
intakes increased significantly in the SG compared to the
CG (P <0.001) and to baseline (P = 0.002) (Table 2). The
addition of sardine to the diet provided 19.3 ± 1.0 g of sar-
dine protein, 3.0 ± 0.2 g of EPA +DHA and 118.5 ± 6.2 mg
of taurine daily (Additional file 2), which contributed about
23 %, 92 % and 72 % of total protein, EPA+DHA and tau-
rine daily intakes in the SG, respectively (Additional file 3).
Comparing to baseline, SG patients reduced their cal-
oric (−203.3 ± 82.0 kcal/day, P = 0.02) and changed the
quality of fat, increasing PUFA (polyunsaturated fatty
acid) and decreasing saturated fatty acid (SFA) intake
(SFA: −2.2 ± 0.7 % of energy, P = 0.03) (Table 2). Regard-
ing to fiber intake, it was observed an increase in the SG
compared to the CG (SG: +1.4 ± 1.3 g/day, CG: −3.3 ±
2.0 g/day, P = 0.03), while the energy intake or other
macronutrient intake did not differ between groups at
baseline or at the end of the study (Table 2).
Glycemic control and insulin sensitivity
The changes in fasting glucose, HbA1c, fasting insulin
and HOMA-IR values were similar and non-statistically
different between the two intervention diets (Table 1).
Only CG decreased significantly Hba1c values compared
to baseline (−0.3 % ± 0.1, P = 0.01). Both groups signifi-
cantly reduced fasting insulin and HOMA-IR levels as
compared with baseline values, and although the patients in
the SG exhibited greater decrease from baseline (SG: −6.1 ±
1.8 mU/L insulin, P = 0.01, −2.3 ± 0.7 HOMA-IR, P = 0.007,
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CG: −3.4 ± 1.5 mU/L insulin, P = 0.02, −1.1 ± 0.7
HOMA-IR, P = 0.04), (Table 1), the mean change from
baseline to 6 months was not different between SG and
CG (Additional file 4).
Erythrocyte membrane fatty acid composition
At the end of the intervention, participants in SG in-
creased both EPA (+0.9 ± 0.2 %, P = 0.001) and DHA
(+1.7 ± 0.2 %, P < 0.001), translated into a net signifi-
cance increase in O3I (+2.6 ± 0.4 %, P < 0.001), (Table 3).
Despite the decrease in arachidonic acid (AA: C20:4n-6),
(−0.9 ± 0.3 %, P = 0.02), there was a net increase in total
PUFAs (P < 0.001). When comparing the two groups, SG
showed a significant increase in EPA (P = 0.008), DHA
(P = 0.001), O3I (P = 0.001) and total PUFAs (P = 0.02) as
compared to CG (Table 3).
Total adiponectin and inflammatory markers
Although there were no significant differences in adipo-
nectin concentrations between groups at 6 months
(Table 1) or comparing the changes over time (SG: +0.9
± 0.4, CG: +0.4 ± 0.5, P = 0.41) (Additional file 3), those
subjects in SG increased significantly the levels of adipo-
nectin from 2.1 ± 0.3 μg/mL at baseline to 3.0 ± 0.3 μg/
mL at 6 months (P = 0.04) (Table 1). Regarding to infla-
matory markers, IL-10 did not show any significant
change after the intervention in the SG (baseline: 1.3 ±
0.1 pg/mL, 6 months: 1.5 ± 0.1 pg/mL, P = 0.09) (Table 1).
In the CG, TNFα concentrations increased significantly
when compared to baseline at the end of the study, (P =
0.05), (Table 1). Nevertheless, these changes in inflam-
matory markers were not different between the two
intervention groups at 6 months (Table 1).
Gut microbiota composition
Although no statistically significant differences were
found in the abundance of the bacterial groups analysed
comparing the SG and the CG at 6 months (Table 4),
phylum Firmicutes were decreased in both groups after
6 months (SG: P = 0.01, CG: P = 0.03) and the Firmicutes/
Table 1 Body weight, glycemic, insulin, adiponectin and inflammatory parameters at baseline and after 6 months of dietary
intervention
Baseline 6 Months
Sardine group
(n = 19)
Control group
(n = 16)
Sardine group
(n = 17)
Control group
(n = 15)
P valuea P value b P within SG c P within CG c
Md/Fe (n) 8/11 8/8 0.64 7/10 7/8 0.76
Age (years) 60.0 ± 1.7 61.2 ± 2.4 0.83 58.7 ± 1.7 59.8 ± 1.9 0.66
Weight (kg) 81.7 ± 3.7 75.8 ± 2.9 0.25 80.5 ± 3.7 75.1 ± 2.8 0.71 0.08 0.35
BMIf (kg/m2) 30.5 ± 1.0 28.8 ± 0.8 0.39 30.0 ± 1.0 28.5 ± 0.8 0.70 0.08 0.44
HbA1cg (%) 6.8 ± 0.1 6.7 ± 0.1 0.59 6.6 ± 0.1 6.4 ± 0.1 0.57 0.08 0.01
Fasting glucose (mg/dL) 138.2 ± 6.5 134.3 ± 5.1 0.99 128.6 ± 4.4 129.1 ± 5.4 0.74 0.18 0.36
Fasting insulin (mU/L) 17.2 ± 1.7 15.1 ± 1.8 0.45 11.1 ± 1.8 11.7 ± 2.4 0.37 0.01 0.02
HOMA-IRh 5.9 ± 0.7 5.0 ± 0.6 0.46 3.6 ± 0.6 3.9 ± 0.9 0.34 0.007 0.04
hs-CRPi (mg/dL) 0.2 ± 0.0 0.2 ± 0.1 0.88 0.2 ± 0.0 0.2 ± 0.1 0.73 0.89 0.53
Total adiponectin (μg/mL) 2.1 ± 0.3 2.0 ± 0.4 0.37 3.0 ± 0.3 2.5 ± 0.4 0.26 0.04 0.16
TNFαj (pg/mL) 5.6 ± 0.2 4.9 ± 0.3 0.44 5.6 ± 0.4 6.1 ± 0.5 0.33 0.71 0.05
IL-6k (pg/mL) 3.5 ± 0.3 3.0 ± 0.3 0.66 3.6 ± 0.4 3.3 ± 0.4 0.91 0.68 0.58
IL-8l (pg/mL) 23.3 ± 3.3 18.7 ± 3.0 0.97 25.3 ± 5.3 18.9 ± 1.3 0.50 0.88 0.91
IL-10m (pg/mL) 1.3 ± 0.1 1.2 ± 0.0 0.28 1.5 ± 0.1 1.3 ± 0.1 0.31 0.09 0.12
Values are mean ± SE
a Intergroup comparisons at baseline by Mann-Whitney’s U test or X2
b Differences between groups at 6 months adjusted for baseline values (ANCOVA)
c Intragroup comparisons by Wilcoxon signed-rank test
d M: male
e F: female
f BMI: Body Mass Index
g HbA1c: glycated hemoglobin
h HOMA-IR: homeostasis model of assessment - insulin resistance
i hs-CRP: high-sensitivity C-reactive protein
j TNFα: tumor necrosis factor alpha
l IL-6: interleukin 6
l IL-8: interleukin 8
m IL-10: interleukin 10
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Bacteroidetes ratio decreased in SG (P = 0.04) (Table 4). E.
coli concentrations were higher at the end of the study in
both SG and CG (SG and CG: P = 0.04) (Table 4). More-
over, the proportions of Bacteroides-Prevotella increased
in the SG (P = 0.004), while there was a decreasing trend
in the Firmicutes/Bacteroidetes ratio in the CG group
(P = 0.06) (Table 4).
Discussion
To our knowledge, the Pilchardus Study is the first study
that has been carried out in drug-naïve T2D patients to
investigate if a 6-month diet rich in sardines improves
glycemic control as compared to a standard diet recom-
mended for T2D. In this sense, this study enhances the
field of nutrition research in diabetes.
Previous reports in patients with T2D showed no im-
provements [13] or small increases in glucose concentra-
tions after a diet rich in fatty fish [14, 15]. Contrasting
with these cited studies [14, 15], the Pilchardus Study
suggests no deleterious effects of a sardine diet on gly-
cemic control without oral antidiabetic drugs, and dur-
ing a period of intervention longer enough to observe
these changes. In the present study, only the CG re-
duced significantly its HbA1c levels at the end of the
study (− 0.3 % ± 0,1), although the clinical relevance of
this value was similar that of the value obtained by the
SG (−0.2 % ± 0,1). An important point were that both
groups managed to delay, through dietary intervention,
the onset of therapy with oral diabetes medication,
maintaining a good glycemic control throughout the
follow-up period (HbA1c between 6.4 and 6.5 %).
Regarding the reduction of insulin and HOMA-IR in
Pilchardus Study, these values were associated with a
slight decrease in body weight in both intervention
groups, in comparison to the results of other studies, in
which weight loss was the main factor [16] or a pre-
dictor of improvement in insulin resistance [17]. For this
reason, our results differ from the aforementioned stud-
ies. In relation to dietary intake, the SG reduced energy
intake from baseline but did not significantly modify the
body weight. Given that underreporting of energy intake
has been previously described in obese patients with
T2D [18], this could be a plausible explanation for this
observation. In the present study SG and also CG de-
creased insulin and HOMA-IR levels. The fact that CG
had both dietary intervention and dietary education may
explain these results, since a variety of approaches in nutri-
tion therapy proves to be effective in improving insulin re-
sistance [2], and dietary education may improve metabolic
control inducing modifications in health behaviors [19].
Relating to possible nutrients of oily fish involved in
their beneficial effects, because of omega 3 fatty acids
supplements failed to yield changes in insulin metabol-
ism in T2D patients [5], some authors emphasized that
other nutrients [20], including oily fish protein and tau-
rine (especially in sardines) could have a role in their in-
sulin sensitive effects, as some studies showed in animal
models with diabetes and metabolic syndrome [6, 7].
Fig. 2 The CONSORT flow diagram
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In Pilchardus Study, we could not found a specific
effect of oily sardine-enriched diet in insulin resistance,
differing from other studies, in which the subjects did
not present T2D but healthy weight or overweight/obes-
ity [20, 21]. The reason might be attributed to the differ-
ences in metabolic state, given that the studies in
subjects with T2D showed the similar results as our
study [13], or no modifications in HOMA-IR [14, 15]. It
could be possible that effects of oily fish intake in T2D
would be dependent on the degree of insulin resistance
and glucose deterioration, or the interplay with other
factors such as multiple medications, genetic background
or macronutrient balance of diet. However, the human
evidence of the effects of oily fish on insulin metabolism
in T2D is limited to 3 studies [13–15], very scarce com-
paring to 9 clinical trials conducted with omega 3 supple-
ments; the most recent including 12.350 with T2D [5, 22].
Therefore, the Pilchardus Study enhances the field of nu-
trition research in diabetes.
In the present study, the inclusion of 100 g of sardines
5 days a week translated to a significant rise in dietary
EPA +DHA (3.0 g) and taurine (118.5 mg), those were
significantly different from CG. Moreover, the protein
and taurine from sardines contributed respectively to
23 % and 72 % of total daily intakes. Therefore, sardine
protein and taurine might contribute at some extent to
the improvement on HOMA-IR in the SG.
Furthermore, we cannot exclude the possible contribu-
tions of olive oil from canned sardines in insulin sensitivity
in SG, since and olive oil has favourable effects on insulin
sensitivity [23]. Regarding fiber intake, SG exhibited an in-
crease in fiber intake as compared to CG at the end of the
dietary intervention. We speculate that the inclusion of
sardines during the study could have determined the diet-
ary pattern of patients, so that they included modifications
that implied a healthier diet, such as to replace refined
cereal products for whole grain cereal products. The
evidence indicates that total and cereal fiber is inversely
related to the risk of T2D [24], and that a whole-grain diet
can improve insulin sensitivity in hyperinsulinemic sub-
jects [25]. Therefore, the increase in fiber intake in SG
probably contributed to reduction of HOMA-IR.
As for adipokine profile, in spite that the changes in
adiponectin levels was not significant between groups,
we observed a 41 % increase in adiponectin levels from
baseline values in SG subjects, double the increase found
Table 2 Nutrient dietary intake at baseline and after 6 months of dietary intervention
Baseline 6 Months
Sardine group
(n = 12)
Control group
(n = 11)
Sardine group
(n = 12)
Control group
(n = 11)
P valuea P value b P within SG c P within CG c
Energy (kcal/day) 1829.5 ± 129.9 1758.5 ± 150.7 0.74 1626.2 ± 89.2 1687.2 ± 128.6 0.30 0.02 0.53
Carbohydrates (g/day) 163.8 ± 13.9 146.8 ± 11.7 0.83 141.6 ± 10.8 136.3 ± 14.1 0.82 0.18 0.18
Protein (g/day) 92.0 ± 6.7 87.3 ± 7.9 0.83 83.9 ± 4.8 83.5 ± 5.0 0.85 0.24 0.42
Fat (g/day) 88.3 ± 4.8 84.4 ± 8.1 0.41 79.2 ± 4.5 83.7 ± 5.8 0.27 0.01 0.86
SFAd (g/day) 25.3 ± 2.7 22.6 ± 3.0 0.41 18.6 ± 1.6 21.6 ± 2.2 0.11 0.003 0.72
MUFAe (g/day) 44.8 ± 2.3 42.0 ± 3.3 0.26 40.6 ± 1.9 43.3 ± 2.8 0.25 0.07 0.66
PUFAf (g/day) 11.4 ± 0.6 12.4 ± 1.6 0.93 13.0 ± 1.2 12.0 ± 1.5 0.21 0.21 0.79
EPAg + DHAh (g/day) 0.4 ± 0.1 0.2 ± 0.02 0.15 3.2 ± 0.1 0.4 ± 0.1 <0.001 0.002 0.16
Total n-3 PUFAi (g/day) 1.6 ± 0.2 1.5 ± 0.2 0.60 4.7 ± 0.2 1.3 ± 0.1 <0.001 0.002 0.12
Taurine (mg/day) 61.0 ± 10.9 53.6 ± 7.6 0.95 168.2 ± 9.4 58.7 ± 6.3 <0.001 0.002 0.53
Fat (% Energy) 44.4 ± 1.9 43.1 ± 1.6 0.53 43.8 ± 0.8 44.9 ± 0.9 0.60 0.58 0.25
SFA (% Energy) 12.3 ± 0.8 11.3 ± 0.8 0.49 10.2 ± 0.4 11.3 ± 0.5 0.06 0.03 0.97
MUFA (% Energy) 22.8 ± 1.4 21.9 ± 1.0 0.65 22.7 ± 0.9 23.8 ± 1.2 0.45 0.58 0.13
PUFA (% Energy) 5.8 ± 0.4 6.2 ± 0.4 0.75 7.1 ± 0.5 6.3 ± 0.4 0.01 0.04 0.72
Dietary fiber (g/day) 15.5 ± 1.3 18.9 ± 2.5 0.41 17.3 ± 1.2 15.1 ± 1.5 0.03 0.08 0.08
Values are mean ± SE
a Intergroup comparisons at baseline by Mann-Whitney’s U test
b Differences between groups at 6 months adjusted for baseline values (ANCOVA)
c Intragroup comparisons by Wilcoxon signed-rank test
d SFA: saturated fatty acid
e MUFA: monounsaturated fatty acid
f PUFA: polysaturated fatty acid
g EPA: eicosapentanoic acid
h DHA: docosahexanoic acid
i n-3 PUFA: omega 3 polyunsaturated fatty acid
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in the CG (21 %). Due to its key role in insulin sensitiv-
ity [26], this adipokine might be one of other factors
involved in the improvement of insulin resistance in the
SG. Some clinical studies have shown the benefits of oily
fish intake in adiponectin, but they were not associated
with an improvement in HOMA-IR [27, 28]. Perhaps
the presence of insulin resistance together with hipoadi-
ponectinemia is needed in order to observe an effect in
the improvement on HOMA-IR, as this is a feature of
T2D [26] and the cited studies [27, 28] did not include
patients with T2D. In addition, since we analysed total
adiponectin but not high-molecular weight adiponectin,
which is the main isoform that influence adiponectin
levels and is related with insulin sensitivity [26], it could
be a reason for not finding higher effects in SG.
In respect of oily fish nutrients that can affect adi-
ponectin, both fish oil and taurine have been reported
to induce an increase in adiponectin levels in humans
Table 4 Gut microbiota composition at baseline and after 6 months of dietary intervention
Baseline 6 Months
Sardine group
(n = 16)
Control group
(n = 14)
Sardine group
(n = 16)
Control group
(n = 14)
P valuec P value d P within SG e P within CG e
Phylum Firmicutesa 0.22 ± 0.002 0.22 ± 0.03 0.56 0.16 ± 0.02 0.15 ± 0.01 0.11 0.01 0.03
Phylum Bacteroidetesa 0.19 ± 0.03 0.12 ± 0.02 0.19 0.17 ± 0.01 0.18 ± 0.01 0.63 1.00 0.08
Firmicutes/Bacteroidetes ratiob 2.59 ± 0.7 1.99 ± 0.5 1.00 1.19 ± 0.1 0.92 ± 0.1 0.75 0.04 0.06
Bacteroides-Prevotella groupa 0.04 ± 0.006 0.05 ± 0.008 0.56 0.06 ± 0.008 0.06 ± 0.01 0.85 0.004 0.12
E.rectale-C.coccoides groupa, f 0.09 ± 0.02 0.09 ± 0.02 0.75 0.08 ± 0.02 0.09 ± 0.02 0.97 0.65 0.78
F.prausnitziia, g 0.02 ± 0.003 0.02 ± 0.004 0.73 0.03 ± 0.005 0.02 ± 0.006 0.54 0.11 0.73
E.colia, h 0.0008 ± 0.0002 0.02 ± 0.02 0.93 0.005 ± 0.002 0.08 ± 0.08 0.35 0.04 0.04
Values are mean ± SE
a 16S rRNA gene copies of the bacterial group / 16S rRNA gene copies of total bacteria
b 16S rRNA gene copies of Firmicutes/ 16S rRNA gene copies of Bacteroidetes
c Intergroup comparisons at baseline by Mann-Whitney’s U test
d Differences between groups at 6 months adjusted for baseline values (ANCOVA)
e Intragroup comparisons by Wilcoxon signed-rank test
f E.rectale-C.coccoides: Eubacterium rectale – Clostridium coccoides
g F.prausnitzii: Faecalibacterium prausnitzii
h E.coli: Escherichia coli
Table 3 EMFA composition at baseline and after 6-month dietary intervention
Baseline 6 Months
Sardine group
(n = 17)
Control group
(n = 15)
Sardine group
(n = 17)
Control group
(n = 15)
P valuea P value b P within SG c P within CGc
EPAd (%) 0.6 ± 0.1 0.7 ± 0.1 0.26 1.5 ± 0.2 0.9 ± 0.1 0.008 0.001 0.51
DHAe (%) 4.7 ± 0.2 5.1 ± 0.2 0.35 6.4 ± 0.3 5.5 ± 0.3 0.001 <0.001 0.11
Total n-3 PUFAsf (%) 6.8 ± 0.3 7.5 ± 0.3 0.19 11.6 ± 0.3 8.2 ± 0.5 <0.001 <0.001 0.11
O3Ig (%) 5.3 ± 0.3 5.8 ± 0.3 0.26 8.0 ± 0.4 6.4 ± 0.5 0.001 <0.001 0.20
AAh (%) 16.4 ± 0.5 17.2 ± 0.7 0.28 15.4 ± 0.5 17.1 ± 0.6 0.04 0.02 0.39
DHGLAi (%) 1.7 ± 0.1 1.7 ± 0.1 0.63 1.7 ± 0.1 1.7 ± 0.1 0.04 0.34 0.03
Total n-6 PUFAsj (%) 34.1 ± 0.9 34.8 ± 1.0 0.44 32.8 ± 0.9 34.6 ± 0.8 0.12 0.05 0.30
Total n-3 PUFAs + n-6 PUFAs (%) 40.9 ± 0.8 42.2 ± 1.1 0.17 44.4 ± 0.8 42.8 ± 0.7 0.02 <0.001 0.95
Values are mean ± SE
aIntergroup comparisons at baseline by Mann-Whitney’s U test
b Differences between groups at 6 months adjusted for baseline values (ANCOVA)
c Intragroup comparisons by Wilcoxon signed-rank test
d EPA, eicosapentanoic acid
e DHA, docosahexanoic acid
f n-3 PUFAs: omega 3 polyunsaturated fatty acids
g O3I: omega-3 index
h AA: arachidonic acid
i DHGLA: dihomo-γ-linolenic acid
j n-6 PUFAs: omega 6 polyunsaturated fatty acids
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[29, 30]. The dose of EPA + DHA from sardines in
our study was 3.0 g per day, in the range of those reported
in fish oil studies [29], but the dose of taurine supplemen-
tation was much higher (3 g per day versus 118.5 mg per
day) than in our study [30]. However, because whole foods
are provided of superior effects over their isolated constit-
uents [31], these two nutrients might be related to the
observed results for adiponectin in SG. Despite this rise in
adiponectin, we did not find any modifications in the in-
flammatory markers studied except for an unexpected rise
in TNFα in the CG. However, some studies revealed bene-
ficial effects of oil fish intake on inflammatory markers,
such as u-CRP, TNFα and IL-6 [28, 32].
Since the main determinant of O3I is LCn-3PUFAs
intake [12], the significant increase of O3I observed in SG
attests to its optimal adherence to dietary intervention. Im-
portantly, SG subjects increased the O3I from 5.3 to 8 %,
reaching the suggested cutoff for protection against ische-
mic heart disease, particularly sudden cardiac death [4].
Another remarkable finding related to EMFA compos-
ition is the net increase in total PUFAs in red blood cells
that was observed in SG. One of the rheological parame-
ters altered in T2D is the deformability of erythrocytes,
which has been found to be reduced compared with
healthy participants [33]. Such stiffness is likely to reduce
microcirculatory flow, impairing diabetes-driven micro-
vascular pathology in the retina and renal glomerulus. In
line with this notion, the shift towards insaturation in ery-
throcite membranes, ensuing increased cell deformability,
has been suggested to counteract microangiopathy in T2D
[34] Therefore, although sardine intake appears to be un-
related to glycemic control, it might contribute toward
limiting vascular co-morbidities associated to T2D.
The Pilchardus Study investigated the impact of a diet
rich in sardines on GM in drug-naïve T2D patients,
showing a decrease in phylum Firmicutes in both groups
and in the Firmicutes/Bacteroidetes ratio in the SG
group over time. These results are in agreement with
studies in obese patients whose GM was enriched in
phylum Firmicutes and the Firmicutes/Bacteroidetes
ratio was higher than in control subjects [35]. The oppos-
ite was found, however, when they lost weight with low-
calorie diets [35] or surgically induced weight loss [36].
There may possibly be an association between the changes
in phylum Firmicutes and in Firmicutes/Bacteroidetes ra-
tio with HOMA-IR, as a recent study in mice found and
association between a decrease in these bacterial groups
and an improvement in insulin resistance [37]. The modi-
fication in GM composition in our study could be related
to dietary interventions, as shifting dietary macronutrients
is proven broadly and rapidly alter the gut microbiome
[38]. We speculate a possible effect of LCn-3PUFA
present in the sardine diet on GM changes, as certain
studies have shown in both mice [39] and infants [40].
In addition, we found increased levels of E. coli in both
groups and raised proportions of Bacteroides-Prevotella
in SG patients. Similar results were found in previous
studies in obese patients with and without T2D after
gastric bypass surgery [36] or following weight loss diets
[41]. Although E. coli is considered a marker of dysbiosis
in T2D [42, 43], only observational studies have estab-
lished these bacterial imbalances without taking into
consideration the diet, which is the main factor affecting
GM [9].
It should be noted that we included only drug-naïve
T2D patients, thus we can rule out any confounding
effect of metformin or insulin on glycemic control or
insulin parameters. Moreover, the long duration of the
nutritional intervention (6 months) and the use of O3I
as a biomarker of LCn-3PUFA confer validity to HbA1c
values and to the dietary compliance of the subjects
assigned to the SG. In our study, we determined the
taurine intake of diets. Given that none of cited stud-
ies provided the intake of this sulfur amino acid, the
Pilchardus Study is specially novel to this point, con-
tributing to enhance the field of nutrition research in
diabetes.
The main limitation of the present study is the small
sample size, which makes it difficult to detect changes
between the groups due to low statistical power. An-
other important limitation is the assessment of insulin
sensitivity using HOMA-IR as it is a measure of basal
insulin sensitivity and does not give information about
the stimulated state. In addition, the determination of
total adiponectin and not high-molecular weight adipo-
nectin could influence the lack of significant increased
in SG compared to CG, considering that this isoform is
the most active. Furthermore, the CG also followed a
dietary intervention, which could have influenced the
results and contributed to producing non-significant
results. A third group control, with no intervention at
all, or a control group under “usual care” would have
been interesting to include, in order to achieve a
stronger contrast of results.
Conclusions
In conclusion, our results suggest that the inclusion of
100 g of sardines 5 days a week during 6 months does
not improve glycemic control, but it could have benefi-
cial effects on cardiovascular risk by achieving optimal
levels of O3I. Furthermore, both dietary interventions
decreased HOMA-IR and altered gut microbiota com-
position in drug-naïve patients with T2D. Further studies
with a greater sample size and extended diet periods
would be needed to corroborate our findings and further
explore the effects and mechanisms by which a sardine
diet could influence metabolic control, adiponectin, in-
flammation and GM composition in patients with T2D.
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